Attached Documents
- Hikma Pharmaceuticals USA Inc., et al.’s reply brief
- Hikma’s merits brief
- Amarin Phamra, Inc., et al.’s merits brief
- Amicus Waxman’s brief in support of Hikma
- Amicus Public Citizen’s brief in support of Hikma
- Amicus Upadhye’s brief in support of Hikma
- Amicus Association for Accessible Medicines’ brief in support of Hikma
- Amici 76 scholars’ brief in support of Hikma
- U.S. government’s motion to participate in oral argument as amicus
- Amicus U.S. government’s brief in support of Hikma
- Amicus Intellectual Property Owners Association’s amicus brief in support of neither party
- Amici professors Gugliuzza and Sherkow’s brief in support of neither party
- Amicus Licensing Executives Society’s brief in support of neither party
- Amicus New York Intellectual Property Law Association’s brief in support of neither party
- Amicus Public Interest Patent Law Institute’s brief in support of neither party
- Amicus Regeneron’s brief in support of Amarin
- Amicus Sanofi’s brief in support of Amarin
- Amici AbbVie, et al.’s brief in support of Amarin
- Amici medical centers’ brief in support of Amarin
- Amicus American Intellectual Property Law Association’s brief in support of Amarin
- Amici Judge Michel, et al.’s brief in support of Amarin
- Amici Pharmaceutical Research and Manufacturers of America, et al.’s brief in support of Amarin
- Federal Circuit’s June 2024 opinion